{"disease":{"id":"borderline-resectable-pancreatic-cancer","name":"borderline resectable pancreatic cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06714604","title":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":432,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT06944587","title":"A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT04698915","title":"Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Galera Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04090463","title":"IORT on Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":100,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT06595160","title":"Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04247165","title":"Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Herlev Hospital","has_results":false},{"nct_id":"NCT06387810","title":"Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06345300","title":"NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06423326","title":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02394535","title":"Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04484909","title":"NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04106856","title":"Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":22,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT07448376","title":"EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT04940286","title":"Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04327986","title":"Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}